Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Six months on, Biohaven succumbs to Pfizer
Biohaven looks to have timed its exit well, giving investors more reason to cheer the $11.6bn buyout.
Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Biohaven’s high-risk bet
There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.
Biotech investors pray for a takeover miracle
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
